See more : Metallus Inc. (MTUS) Income Statement Analysis – Financial Results
Complete financial analysis of Mallinckrodt plc (MNK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mallinckrodt plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Greenlam Industries Limited (GREENLAM.NS) Income Statement Analysis – Financial Results
- UA Multimedia, Inc. (UAMM) Income Statement Analysis – Financial Results
- Yutaka Giken Co.,Ltd. (7229.T) Income Statement Analysis – Financial Results
- Prosegur Cash, S.A. (CASH.MC) Income Statement Analysis – Financial Results
- Telecom Italia S.p.A. (TIAOF) Income Statement Analysis – Financial Results
Mallinckrodt plc (MNK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mallinckrodt.com
About Mallinckrodt plc
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.21B | 2.21B | 3.16B | 3.22B | 3.22B | 3.38B | 3.35B | 2.54B | 2.21B | 2.06B | 2.02B |
| Cost of Revenue | 1.32B | 1.32B | 1.54B | 1.74B | 1.74B | 1.57B | 1.53B | 1.49B | 1.34B | 1.18B | 1.09B | 1.11B |
| Gross Profit | 891.70M | 891.70M | 669.40M | 1.42B | 1.47B | 1.66B | 1.86B | 1.85B | 1.20B | 1.03B | 964.80M | 914.90M |
| Gross Profit Ratio | 40.37% | 40.37% | 30.24% | 44.95% | 45.75% | 51.41% | 54.87% | 55.38% | 47.36% | 46.62% | 46.92% | 45.25% |
| Research & Development | 205.20M | 205.20M | 290.80M | 349.40M | 361.10M | 277.30M | 262.20M | 185.10M | 166.90M | 166.50M | 144.10M | 141.50M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 581.80M | 581.80M | 884.10M | 831.00M | 834.10M | 920.90M | 925.30M | 1.17B | 842.10M | 611.40M | 551.70M | 532.50M |
| Other Expenses | 0.00 | 22.00M | 7.40M | 63.60M | 30.90M | 6.00M | -600.00K | 8.10M | 1.80M | 800.00K | 1.00M | 2.90M |
| Operating Expenses | 787.00M | 787.00M | 1.17B | 1.18B | 1.20B | 1.20B | 1.19B | 1.35B | 1.01B | 777.90M | 695.80M | 674.00M |
| Cost & Expenses | 2.10B | 2.10B | 2.72B | 2.92B | 2.94B | 2.76B | 2.71B | 2.85B | 2.35B | 1.96B | 1.79B | 1.78B |
| Interest Income | 1.90M | 1.90M | 5.90M | 9.50M | 8.20M | 4.60M | 1.30M | 1.00M | 1.50M | 300.00K | 400.00K | 200.00K |
| Interest Expense | -222.60M | 222.60M | 261.10M | 309.00M | 370.20M | 369.10M | 384.60M | 255.60M | 82.60M | 19.50M | 500.00K | 600.00K |
| Depreciation & Amortization | 328.90M | 675.80M | 885.20M | 951.10M | 852.10M | 808.30M | 834.50M | 672.50M | 275.90M | 139.60M | 130.90M | 119.80M |
| EBITDA | -723.50M | 804.40M | 393.00M | 1.27B | 1.17B | 468.70M | 1.50B | 1.18B | 473.30M | 254.30M | 401.30M | 363.80M |
| EBITDA Ratio | -32.76% | 36.42% | 17.76% | 40.01% | 36.30% | 14.55% | 44.45% | 35.27% | 18.63% | 11.50% | 19.52% | 17.99% |
| Operating Income | -1.05B | 128.60M | -492.20M | 314.10M | -3.72B | 420.10M | 617.30M | 461.80M | -284.10M | 148.70M | 235.20M | 240.70M |
| Operating Income Ratio | -47.65% | 5.82% | -22.24% | 9.93% | -115.71% | 13.04% | 18.26% | 13.80% | -11.18% | 6.72% | 11.44% | 11.91% |
| Total Other Income/Expenses | 222.60M | -958.40M | -468.60M | -1.91B | -331.10M | -358.50M | -383.90M | -246.50M | -79.30M | -18.40M | 900.00K | 2.50M |
| Income Before Tax | -829.80M | -829.80M | -960.80M | -1.59B | -4.05B | 61.60M | 233.40M | 215.30M | -363.40M | 130.30M | 236.10M | 243.20M |
| Income Before Tax Ratio | -37.57% | -37.57% | -43.41% | -50.32% | -126.01% | 1.91% | 6.90% | 6.43% | -14.30% | 5.89% | 11.48% | 12.03% |
| Income Tax Expense | -112.40M | -106.30M | 8.90M | -584.30M | -430.10M | -1.71B | -255.60M | -92.90M | -44.80M | 70.20M | 94.80M | 86.20M |
| Net Income | -717.40M | -723.50M | -969.70M | -1.01B | -3.61B | 2.13B | 643.70M | 324.70M | -319.30M | 61.10M | 134.60M | 150.70M |
| Net Income Ratio | -32.48% | -32.76% | -43.81% | -31.85% | -112.17% | 66.25% | 19.04% | 9.70% | -12.57% | 2.76% | 6.55% | 7.45% |
| EPS | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.85 | 5.82 | 2.78 | -4.92 | 1.06 | 2.33 | 2.61 |
| EPS Diluted | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.80 | 5.77 | 2.75 | -4.92 | 1.06 | 2.33 | 2.61 |
| Weighted Avg Shares Out | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.70M | 110.60M | 115.80M | 64.90M | 57.70M | 57.70M | 57.70M |
| Weighted Avg Shares Out (Dil) | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.90M | 111.50M | 117.20M | 64.90M | 57.80M | 57.70M | 57.70M |
MALLINCKRODT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Options
The Law Offices of Frank R. Cruz Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors
Mallinckrodt stock rises after disclosure of another one-week delay in the $200 million opioid-settlement payment
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors with Over $1 Million in Losses to Secure Counsel Before Important Deadline in Securities Class Action – MNK, MNKPF
Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!
Levi Strauss shares tumble on outlook cut, Mallinckrodt and Alibaba shares rise and more stocks on the move
Mallinckrodt open to proposed transactions as it struggles to pay opioid settlement; stock rallies
Mallinckrodt in Talks to Cut Opioid Settlement by Up to $1 Billion
Mallinckrodt makes late interest payment
Mallinckrodt delays $200 million opioid-settlement payment by another week
Source: https://incomestatements.info
Category: Stock Reports